No Data
No Data
Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2024 financial results on Wednesday, July 31, 2024. Bausch
Express News | Bausch + Lomb : Raymond James Initiates Coverage With Outperform Rating; Price Target $19
Raymond James Initiates Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $19
Raymond James analyst Gary Nachman initiates coverage on $Bausch + Lomb Corp.(BLCO.US)$ with a buy rating, and sets the target price at $19.According to TipRanks data, the analyst has a success rate
RBC Capital on Bausch + Lomb's Miebo, Xiidra, Prescription Numbers
RBC Capital notes that total prescriptions (TRx) for Bausch + Lomb's prescription for dry eye disease (DED), Miebo, increased week over week, while Xiidra (also for dry eye) printed a year over year d
Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief
New Online Resource, KnowYourDryEye.com, Aims to Increase Awareness and Education Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today
China International Capital Corporation: Colored contact lenses promote demand upgrade, and manufacturing business enters the golden development period.
Terminal demand upgrades, technological innovation, and changes in the market landscape will drive rapid development in the domestic industry chain. Contact lenses and colored contact lenses will usher in new development opportunities and are expected to continue to maintain a strong growth trend in the next few years.
Benjamin’s : New CEO